Sherly Mosessian, Ph.D.
Chief Scientific Officer
Dr. Mosessian earned her bachelor’s degree in Biochemistry, followed by her Ph.D from UCLA Department of Molecular, Medical Pharmacology, with publications in tumor signaling, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. She joined the SOFIE team in 2021 as the Vice President of Clinical and Regulatory Affairs leading the clinical development of FAPI diagnostic. She has now been promoted to Chief Scientific Officer in 2022. Prior to joining SOFIE, she served as a Chief Administrative Officer at UCLA and oversaw the establishment of a current Good Manufacturing Process (cGMP) facility in support of Position Emission Tomography (PET) radiopharmaceuticals production for research and clinical service. She has successfully established a pathway at UCLA Department of Pharmacology to translate PET imaging agents from bench to the clinic in a time and cost-efficient manner.
In addition to her expertise in biomedical research, she has served in an executive leadership capacity in technology, having co-led the establishment of DGIT, the integrated information technology organization in support of the research and education mission of UCLA School of Medicine.
Dr. Mosessian is strategic minded, results focused and embraces a culture of collaboration and teamwork. She is Armenian and having immigrated to the United States at a young age, values the importance of diversity/inclusion, seeking opportunities and having a strong work ethic. She is a proud wife of her South African Husband, Hennie, and they have a lovely daughter, Hailey.